Skip to content
Review Open access

Management of Multiple Sclerosis: Incorporating Recent Advances in Pathophysiology and Diagnosis to Guide Treatment Strategies

Sep 2026 · Drugs · Vol 86, pp. 1813 - 1839 · 0 citations · 263 references
Medicine

TL;DR

Emerging imaging and fluid biomarkers, including brain and spinal cord atrophy metrics, neurofilament light chain, glial fibrillary acidic protein, and paramagnetic rim lesions, may improve biological stratification and therapeutic decision making, although further validation is needed.

Abstract

Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disorder of the central nervous system for which more than 20 disease-modifying therapies (DMTs) are currently available. Recent advances in diagnostic criteria, biomarker development, and understanding of disease biology have challenged traditional phenotype-based treatment paradigms and created new opportunities for individualized therapeutic strategies. The 2024 McDonald diagnostic criteria expand the biological definition of MS through incorporation of advanced MRI biomarkers, thereby supporting earlier diagnosis and potentially earlier treatment initiation. Aging influences both disease pathobiology and treatment risk–benefit balance, contributing to reduced focal inflammatory activity, increased progression, diminished regenerative capacity, and greater susceptibility to infections and comorbidities. These observations have important implications for treatment initiation, sequencing, escalation, de-escalation, and discontinuation. Current monitoring strategies remain centered on relapses, disability measures, and MRI lesion activity, but each has important limitations. Emerging imaging and fluid biomarkers, including brain and spinal cord atrophy metrics, neurofilament light chain, glial fibrillary acidic protein, and paramagnetic rim lesions, may improve biological stratification and therapeutic decision making, although further validation is needed. Safety considerations vary substantially across DMT classes. Real-world data have advanced our understanding of long-term risks, particularly with B-cell-depleting therapies. Novel therapeutic approaches in development are intended to more effectively target compartmentalized central nervous system inflammation and progression biology while potentially reducing systemic immunosuppression. As a result of these factors, MS management is evolving.

Read PDF

Similar papers

Review Open access Sep 2026

Multiple sclerosis: Early diagnosis, disease-modifying therapies, and impact on disability

Multiple sclerosis is now diagnosed and treated earlier than in previous therapeutic eras, but the clinical value of this shift depends on whether earlier recognition leads to prevention of irreversible disability rather than simply earlier labeling of disease. This narrative review examines the relationship among cont...

Bárbara Alexandra Ossuchi de Oliveira, Laura Leme de Araújo Rodrigues da Silva, Luísa Craide Haenssgen et al. · 0 citations
Review Open access Sep 2026

MULTIPLE SCLEROSIS: NEW IMMUNOMODULATORY STRATEGIES AND BIOMARKERS

Introduction and purpose: Multiple Sclerosis (MS) disability accumulation is driven primarily by compartmentalized, subclinical neuroinflammation and diffuse neurodegeneration, termed smouldering MS. While traditional disease-modifying therapies (DMTs) control peripheral relapses and focal MRI activity, halting this pr...

Natalia Kitala, Justyna Karliczek, K. Nycz et al. · 0 citations
Review Open access Oct 2026

Multiple Sclerosis: Current Perspectives on Disease Mechanisms, Clinical Management, and Therapeutic Advances

Background: Multiple sclerosis (MS) is a disease whose incidence has been increasing statistically alongside the development and wider availability of advanced diagnostic methods. Despite extensive research investigating its etiology, clinical course, and therapeutic approaches, considerable uncertainty remains regardi...

Bartosz Seroczyński, Anna Zyskowska, Gabriela Pyrka et al. · 0 citations
Review Oct 2026

Multiple sclerosis: Advances in diagnosis, biomarkers, and disease management.

Multiple sclerosis (MS) care has advanced rapidly across diagnosis, biomarkers, and disease-modifying therapy. The 2024 revision of the McDonald criteria enables earlier and more biologically grounded diagnosis through the cerebrospinal fluid (CSF) kappa free light chain (KFLC) index, the central vein sign (CVS), and p...

Ethan Grund, Anne H. Cross, S. Chahin · 0 citations
Review 2026

Parkinson's disease-Crucial advances and on-going challenges.

This review focuses on some of the groundbreaking advances and the immediate challenges faced by researchers, clinicians, and individuals with PD, as they collaborate to address the great-and ever-growing-clinical need in PD.

Grażyna Söderbom · 0 citations
Review Open access Sep 2026

Spinal cord imaging in multiple sclerosis: from diagnosis to disease progression

The characteristic MRI features of MS SC lesions and their key inflammatory and non-inflammatory differentials are described, and the role of SC imaging in diagnosis is examined, particularly in the context of the 2024 revisions to the McDonald criteria.

T. Koren, Jashan Dugal, Dong-Ang Wang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.